ZURA BIO LIMITED Increase (Decrease) in Prepaid Expense and Other Assets
ZURA BIO LIMITED (ZURA) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.34 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- ZURA BIO LIMITED increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.49M, a 33.04% increase year-over-year.
- ZURA BIO LIMITED increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$1.49M.
- ZURA BIO LIMITED increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$372.00K, a 124.93% decline year-over-year.
- ZURA BIO LIMITED increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.03M.
- ZURA BIO LIMITED increase (decrease) in prepaid expense and other assets for fiscal 2025 was $657.00K, a 45.66% decline from fiscal 2024.
- ZURA BIO LIMITED increase (decrease) in prepaid expense and other assets for fiscal 2024 was $1.21M, a 46.01% increase from fiscal 2023.
- ZURA BIO LIMITED increase (decrease) in prepaid expense and other assets for fiscal 2023 was $828.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 5 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 8 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 11 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.34K 10-Q · filed 2026-08-11 | -$370.66K derived: sum of 3 quarters · filed 2026-08-11 | $658.09K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$1.49M 10-Q · filed 2026-05-07 | -$1.86M derived: sum of 2 quarters · filed 2026-05-07 | -$836.25K derived: sum of 3 quarters · filed 2026-05-07 | $287.00K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $656.75K derived: sum of 2 quarters · filed 2026-03-19 | $1.78M derived: sum of 3 quarters · filed 2026-08-11 | $657.00K 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.15M derived: sum of 2 quarters · filed 2026-08-11 | $1.03M 10-Q · filed 2025-11-13 | $2.52M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $249.00 10-Q · filed 2026-08-11 | $249.00K 10-Q · filed 2025-08-14 | $1.49M derived: sum of 3 quarters · filed 2026-08-11 | $1.21M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | -$1.12M 10-Q · filed 2026-05-07 | $369.00K derived: sum of 2 quarters · filed 2026-05-07 | $91.00K derived: sum of 3 quarters · filed 2026-05-07 | $466.00K derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.21M derived: sum of 2 quarters · filed 2026-03-19 | $1.59M derived: sum of 3 quarters · filed 2026-03-19 | $1.21M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | -$278.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $97.00K derived: sum of 2 quarters · filed 2025-11-13 | -$283.00K 10-Q · filed 2025-11-13 | $21.00K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $375.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$5.00K 10-Q · filed 2025-08-14 | $299.00K derived: sum of 3 quarters · filed 2025-08-14 | $502.00K derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$380.00K 10-Q · filed 2025-05-08 | -$76.00K derived: sum of 2 quarters · filed 2025-05-08 | $127.00K derived: sum of 3 quarters · filed 2025-05-08 | $235.00K derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $507.00K derived: sum of 2 quarters · filed 2025-03-25 | $615.00K derived: sum of 3 quarters · filed 2025-03-25 | $828.00K 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | $203.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $311.00K derived: sum of 2 quarters · filed 2024-11-07 | $524.00K 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | $108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $321.00K 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | $213.00K 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | $209.00K 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | $211.00K 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | $24.00K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |